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METHODS: 604 men with clinical suspicion of prostate cancer underwent multiparametric MRI (scored on a 1-5 Likert scale) followed by cognitively registered transperineal MRI-TB at a single centre in a 30-month period. Multi-parametric MRI included T2-weighted, diffusionweighted and dynamic-contrast enhanced sequences reported by an expert uro-radiologist. Factors influencing detection of clinically significant cancer by MRI-TB were investigated with a multivariate logistic regression using STATA. Multiple imputation was carried out to account for missing data.
RESULTS: In the 604 men, mean age was 65 and median was PSA 7.1. Significant cancer was detected in 390 men (65%). The multivariate analysis adjusting for key confounders showed that factors significantly associated with clinically significant cancer detection included MRI-Likert score (p<0.0001), MRI coil strength (p¼0.0013), prior biopsy status (biopsy naive, previous negative biopsy, previous positive biopsy, p¼0.0016) and PSA (p¼0.0135). Factors not associated with detection of significant cancer included anaesthetic (general versus local,p¼0.1274), abnormal digital rectal examination (p¼0.0918), surgeon (p¼0.1724) and location of tumour (anterior vs posterior, p¼0.5825; basal vs apical, p¼0.9204).
CONCLUSIONS: Key factors that influence the odds of detection of clinically significant cancer have been identified. This study validates the MRI-Likert score as one of the strongest predictors of clinically significant cancer detection. It highlights the importance of presenting PSA and MRI coil strength. Notably, this data also highlights that digital rectal exam finding is not very reliable, consistent with previous studies. Of particular importance, this data supports the feasibility of a local anaesthetic-only approach for transperineal targeted biopsy which has major healthcare delivery and health resource use benefits. 
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INTRODUCTION AND OBJECTIVES:
Sepsis is a significant complication following transrectal ultrasound-guided prostate biopsy (TRUSBx). Ciprofloxacin and gentamicin are commonly used for prophylaxis, however there is emerging evidence for an increase in incidence of resistant enteric organisms observed worldwide. We investigate the effect of rectal swab cultures and sensitivities for targeted prophylactic antimicrobial regimes in reducing the risk of sepsis following TRUSBx METHODS: All patients had confirmed negative urinalysis prior to biopsy. 609 patients (Group A) received a prophylactic antimicrobial regime of a single intravenous dose of gentamicin 240mg, rectal metronidazole 1g and oral ciprofloxacin 500mg twice daily for 3 days. Due to a significant incidence of ciprofloxacin and gentamicin resistance in patients admitted with sepsis following TRUBx, our local antibiotic recommendations changed. The subsequent 231 patients (Group B) had rectal swab cultures and sensitivities performed prior to biopsy. Patients with rectal flora organisms resistant to ciprofloxacin or gentamicin received targeted antimicrobial prophylaxis consisting of a single dose oral fosfomycin 3g, intravenous amikacin 750mg and rectal metronidazole 1g. Data was collected for rectal swab cultures, antibiotic regime used, readmission with sepsis within 14 days and blood or urine cultures results on admission.
RESULTS: In group A (standard ciprofloxacin-based regime), 12 of 609 (1.9%) patients were admitted with sepsis following biopsy. E.coli was the most common pathogen detected. Of the 7 patients with positive urine or blood cultures, 4 (57%) were ciprofloxacin-and gentamicin-resistant and 2 (29%) were ciprofloxacin-resistant only. In group B, 38 of 231 (16.5%) patients had ciprofloxacin or gentamicin resistant rectal flora and received the targeted antimicrobial prophylaxis regime (25 ciprofloxacin-resistant only, 3 gentamicin-resistant only, 10 ciprofloxacin-and gentamicin-resistant). Overall in group B, 5 of 231 (2.1%) patients were readmitted with sepsis despite receiving targeted combination of prophylactic antibiotics based on their rectal swab cultures. Of these patients, 2 had grown ciprofloxacin-resistant organisms on rectal swab and received the appropriate antimicrobial prophylaxis regime. The difference between the two groups was not statistically significant (p¼0.86).
CONCLUSIONS: The incidence of ciprofloxacin-resistant flora in our community is significant (15.2%). The risk of sepsis following TRUSBx was overall low, however the use of rectal swab cultures and targeted combination of antibiotic regimes did not seem to reduce the risk any further.
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PD43-08 COMPLICATION RATES FOR OUTPATIENT,TRANSRECTAL, IN-BORE MRI-GUIDED BIOPSY: SEVEN YEARS' EXPERIENCE
John Feller*, Bernadette Greenwood, Stuart May, Indian Wells, CA INTRODUCTION AND OBJECTIVES: The morbidity and mortality associated with TRUS biopsy has been well documented over the past three decades. Acute urinary retention, rectal bleeding, hematuria and hematospermia, uncomplicated urinary tract infection and urosepsis have all been reported at rates between 2-4%. Mortality is rare at less than 0.4%. The purpose of this study is to assess the rates of morbidity with reduced number of cores, targeted to only the tumor suspicious region under MRI-guidance in an outpatient setting.
METHODS: From 2009 to 2016, 3000 men received mpMRI of the prostate. Of those men, 700 underwent in-bore, MRI-guided biopsy in an outpatient setting. All MR guided biopsies were performed using a 1.5 Tesla Philips Achieva XR system (Philips Healthcare, Best, The Netherlands) for both mpMRI image acquisition and in-bore MRI-guided biopsy. DynaCAD and DynaLOC (Invivo, Orlando, FL, USA) software were used for image analysis and biopsy planning. A fully-automatic, titanium biopsy gun was inserted using the DynaTRIM positioning hardware (Invivo, Orlando, FL, USA). Two thirds of the patients undergoing mpMRI were recommended to undergo MR guided biopsy. Of those, 700 underwent MR guided in-bore biopsy. One third of the patients did not undergo prostate biopsy as a result of a negative mpMRI, reducing the number of prostate biopsies in this population.
RESULTS: Of the 700 men who underwent MRI-guided biopsy, only 0.8% experienced complications. Targeting the lesion and reducing the number of cores acquired may reduce morbidity associated with random, systematic biopsy. The average number of tumor suspicious regions identified on mpMRI was1.8 and the average number of core biopsies taken with each MRI-GB was 3.5 cores as opposed to the 12-18 cores taken on average with systematic TRUS Bx. The MRI-GB procedure time on average did not exceed 30 min.
CONCLUSIONS: In the current cost-containment environment in healthcare, any reduction in hospital admissions is welcomed. Transrectally delivered, outpatient MRI-guided biopsy may be a means to that end. Limiting the number of cores acquired by targeting biopsy only to MR-visible tumor suspicious regions results in a 0.8% complication rate in our experience. The MRI-GB procedure can be performed quickly and safely in an outpatient setting with or without conscious sedation.
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